HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- ‘Educational curve’ required before biosimilars are fully embraced in cancer treatment armamentarium
-
- Liquid biopsies offer ‘transformative’ potential for detection of aggressive lymphomas John Sweetenham, MD, FRCP, FACP
- Device for open liver surgery gains FDA 510(k) clearance
- FDA approves cobas KRAS Mutation Test for metastatic colorectal cancer
- FDA grants breakthrough therapy designation to venetoclax for CLL with 17p deletion
- FDA grants orphan drug designation to Cantrixil for ovarian cancer
- FDA grants orphan drug designation to Reolysin for gastric cancer
- FDA grants orphan drug designation to Samcyprone for malignant stage IIb to IV melanoma
- FDA grants orphan drug designation to tremelimumab for malignant mesothelioma
-
- FDA grants priority review status for idarucizumab
- Active surveillance avoids urinary, sexual declines of radical prostatectomy
- Carboplatin noninferior to cisplatin for metastatic, recurrent cervical cancer
- Circulating tumor DNA predictive biomarker for patients with DLCBL
- Cixutumumab fails to enhance activity of ADT in prostate cancer
- Combined surgical diagnostic tools improve gross total resection, not survival, in glioma
- Geriatric patients with cancer at risk for potentially inappropriate medication use
- HSCT associated with increased risk for fractures
-
- Ibrutinib safe, effective in previously treated Waldenström’s macroglobulinemia
- Joint aspiration safe in children with acute hemarthrosis, severe hemophilia A
- Laparoscopic, open surgery yield similar outcomes for rectal cancer
- Loss of TGF-beta signaling in breast cancer impairs response
- Outpatient treatment safe for select patients with acute PE
- Parenchymal preservation reduces mortality after hepatectomy
- Poor outcomes likely for ibrutinib-resistant patients with mantle cell lymphoma
- Racial, ethnic disparities exist in choosing provider for breast cancer care
-
- Radical nephrectomy confers low risk for renal dysfunction in Wilms’ tumor survivors
- RAI treatment may increase second primary malignancy risk among children, young adults with thyroid cancer
- RECESS: Red cell storage duration fails to affect outcomes in patients undergoing cardiac surgery
- Subclinical diagnoses may skew thyroid cancer survival data
- Surgery improves survival rates for patients with lung cancer
- Transfused fresh red cells fail to improve outcomes in critically ill adults
- Vitamin D deficiency linked to acute pain in children with sickle cell disease
- AACR recognizes several researchers
-
- ASH announces training program participants
- Lebwohl begins American Academy of Dermatology presidency term
- Scientist joins cancer institute
- Adjuvant chemotherapy associated with shorter survival in LCNEC
- Augmented therapy improves outcomes for children with high-risk Wilms' tumor
- Balance between benefits, harms key to limiting overdiagnosis in melanoma screening
- Black women demonstrate denser breast tissue than white women
- Certain gene mutations linked to olaparib response in prostate cancer
-
- Clinical, behavioral factors predict lung cancer recurrence
- Durable response to T-VEC, GM-CSF linked to longer OS
- Elotuzumab combination prolongs PFS in relapsed multiple myeloma
- Genetic information influences lung cancer risk, may improve adherence
- HPV vaccine offers multisite protection, even among previously exposed women
- Identification of immunotherapy biomarkers may prove 'very difficult'
- Induction therapy conferred no survival benefit in locally advanced thymomas
- Long-term aspirin use may reduce gastrointestinal cancer risk
-
- MPDL3280A shows promise in metastatic triple-negative breast cancer
- Next-generation sequencing increases actionable mutation detection in malignant melanoma
- Nicotinamide reduces rate of new nonmelanoma skin cancers in high-risk patients
- Plasmid IL-12 electroporation shows promise in melanoma
- Pneumonectomy after neoadjuvant chemoradiation safe, effective in locally advanced NSCLC
- Simultaneous treatment with ipilimumab, nivolumab improves outcomes in advanced melanoma
- SLNB in pure desmoplastic melanoma remains controversial
- Speaker: Screening, diagnosis of melanoma has become increasingly reliant on technology
-
- T-cell immunotherapy appears effective in post-HSCT lymphoproliferative disorder